MedPath

Takeda Pharmaceutical Company Ltd

🇯🇵Japan
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/

A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection

Not yet recruiting
Conditions
Cytomegalovirus (CMV)
Interventions
First Posted Date
2024-08-29
Last Posted Date
2024-08-29
Lead Sponsor
Takeda
Target Recruit Count
250
Registration Number
NCT06577363
Locations
🇯🇵

Takeda selected site, Tokyo, Japan

A Study of Cytomegalovirus (CMV) Infection After Kidney Transplant in Adults in the United Kingdom

Recruiting
Conditions
Cytomegalovirus (CMV)
Interventions
Other: No Intervention
First Posted Date
2024-08-23
Last Posted Date
2025-05-13
Lead Sponsor
Takeda
Target Recruit Count
672
Registration Number
NCT06568055
Locations
🇬🇧

RaDaR (part of the UK Kidney Association), Bristol, Southwestern England, United Kingdom

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants with Primary Immunodeficiency

Recruiting
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Drug: Immune Globulin Subcutaneous (Human), 20% Solution
First Posted Date
2024-08-21
Last Posted Date
2025-02-20
Lead Sponsor
Takeda
Target Recruit Count
100
Registration Number
NCT06565078
Locations
🇯🇵

Takeda selected site, Tokyo, Japan

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Phase 4
Recruiting
Conditions
Colorectal Cancer
Interventions
First Posted Date
2024-08-20
Last Posted Date
2025-05-04
Lead Sponsor
Takeda
Target Recruit Count
78
Registration Number
NCT06562543
Locations
🇺🇸

Central Alabama Research, Birmingham, Alabama, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Ironwood Cancer and Research Centers, Gilbert, Arizona, United States

and more 41 locations

A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

Recruiting
Conditions
Cytomegalovirus (CMV)
Interventions
First Posted Date
2024-08-15
Last Posted Date
2024-11-20
Lead Sponsor
Takeda
Target Recruit Count
168
Registration Number
NCT06555432
Locations
🇰🇷

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

Not yet recruiting
Conditions
Acquired Hemophilia A
Interventions
First Posted Date
2024-08-13
Last Posted Date
2025-04-08
Lead Sponsor
Takeda
Target Recruit Count
9
Registration Number
NCT06550882

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3
Recruiting
Conditions
Plaque Psoriasis
Interventions
First Posted Date
2024-08-12
Last Posted Date
2025-04-17
Lead Sponsor
Takeda
Target Recruit Count
1300
Registration Number
NCT06550076
Locations
🇺🇸

Total Dermatology, Birmingham, Alabama, United States

🇺🇸

University of Alabama Hospital - Whitaker Clinic -, Birmingham, Alabama, United States

🇺🇸

Cahaba Dermatology Skin Health Center, Hoover, Alabama, United States

and more 269 locations

A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

Recruiting
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Other: No Intervention
First Posted Date
2024-08-05
Last Posted Date
2025-05-21
Lead Sponsor
Takeda
Target Recruit Count
30
Registration Number
NCT06538064
Locations
🇺🇸

Eisenhower Neurology Specialty Clinic, Rancho Mirage, California, United States

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

Recruiting
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Other: No Intervention
First Posted Date
2024-07-22
Last Posted Date
2024-10-01
Lead Sponsor
Takeda
Target Recruit Count
1000
Registration Number
NCT06512454
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

🇩🇪

Universitätsklinikum Aachen AöR, Aachen, North Rhine-Westphalia, Germany

A Study of TAK-861 in People With Narcolepsy Type 1

Phase 3
Active, not recruiting
Conditions
Narcolepsy Type 1
Interventions
Drug: Placebo
First Posted Date
2024-07-17
Last Posted Date
2025-03-14
Lead Sponsor
Takeda
Target Recruit Count
105
Registration Number
NCT06505031
Locations
🇦🇹

Takeda Site 22, Linz, Austria

🇧🇪

Takeda Site 25, Ghent, Belgium

🇧🇪

Takeda Site 24, Leuven, Belgium

and more 25 locations
© Copyright 2025. All Rights Reserved by MedPath